Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The vaccine is under FDA review
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
It is a two dose vaccine to be administered intramuscularly at 28 days apart
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Subscribe To Our Newsletter & Stay Updated
